Long-term Pulmonary Outcomes After Infection With Sars-CoV-2

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to assess the long-term outcomes after hospital admission with Covid-19 with respect to pulmonary function, physical capacity, imaging, quality of life and socioeconomic outcomes.

Detailed Description
-----------------
Patients will be invited to follow-up visits 3 and 12 months after hospitalization with COVID19. Inclusion will take place during 2020. We expect to enroll 180 non-ICU patients and 36 ICU patients.

Official Title
-----------------
Long-term Pulmonary Outcomes After Infection With Sars-CoV-2

Conditions
-----------------
Sars-CoV2, Covid19

Intervention / Treatment
-----------------
* Diagnostic Test: Imaging of the lungs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infection with Sars-CoV-2 Exclusion Criteria: Unable to attend hospital visits due to frailty or severe disease Unable to understand and complete questionnaires due to intellectual or language limitations / deficits

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Imaging of the lungs|After hospital admissions with COVID19 patients will come for two clinical visits to complete a number of questionnaires, pulmonary function testing, six-minute walk test, blood sampling and imaging of the lungs.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Imaging of the lungs | Expert evaluation | 3 months after discharge | 
| Imaging of the lungs | Expert evaluation | 12 months after discharge | 
| Pulmonary function tests | Liter | 3 months after discharge | 
| Pulmonary function tests | Liter | 12 months after discharge | 
| Six-minute walk test | Walking distance (meters) and change in oxygen saturation. | Performed 3 months after discharge | 
| Six-minute walk test | Walking distance (meters) and change in oxygen saturation. | Performed 12 months after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Short Form-36 (SF-36) questionnaire | 0-100 scale. The lower the score, the more disability. | 3 months after discharge | 
| Short Form-36 (SF-36) questionnaire | 0-100 scale. The lower the score, the more disability. | 12 months after discharge | 
| Fatigue Assessment Score | 10-50 score. The higher the score, the more fatigue | 3 months after discharge | 
| Fatigue Assessment Score | 10-50 score. The higher the score, the more fatigue | 12 months after discharge | 
| Cognitive sore (MOCA) | 0-30. The lower the score, the more cognitive impairment | 3 months after discharge | 
| Cognitive sore (MOCA) | 0-30. The lower the score, the more cognitive impairment | 12 months after discharge | 
| Hospital anxiety and Depression score (HADS) | 0-21. The higher the score, the more risk of anxiety or depression. | 3 months after discharge | 
| Hospital anxiety and Depression score (HADS) | 0-21. The higher the score, the more risk of anxiety or depression. | 12 months after discharge | 
| Comorbidities | Any pre-COVID-19 comorbidity and treatment with immmunosuppressants will be registered. | 12 months after discharge | 
| Blood sample at routine follow up. | Change in outcomes between discharge and follow-up visits will be evaluated | 3 months after discharge | 
| Blood sample at routine follow up. | Change in outcomes between discharge and follow-up visits will be evaluated | 12 months after discharge | 
| Biobanking of blood | Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence. | 3 months after discharge | 
| Biobanking of blood | Knowledge regarding COVID19 is drastically evolving. Biobanking makes it possible to investigate blood samples in the future corresponding to ongoing evidence. | 12 months after discharge |